A Prussian Blue Nanozyme‐Adjuvanted Vaccine Presenting Phosphocholine Antigens for Induction of Immunotolerance in Inflammatory Bowel Disease
Advanced Science · 2026
DOI: 10.1002/advs.202522027 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Jingyi Sheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China. Hauptthemen laut MEDLINE: Ferrocyanides, Phosphorylcholine, Inflammatory Bowel Diseases, Antigens. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a complex disorder characterized by chronic intestinal inflammation and impaired barrier function, for which effective long‐term therapies remain elusive. To address this challenge, we developed a novel nano‐vaccine that combines Prussian blue nanozymes (PBNZs) adjuvants with a ferritin carrier loaded with phosphorylcholine (PC), an autoimmune‐related antigen (Ferritin‐PC@PBNZs). This vaccine aims to provide sustained protection and therapeutic benefits for IBD through an active immunization strategy. This vaccine leverages the ferritin carrier to effectively present PC antigens, while simultaneously enhancing antigen uptake and activating dendritic cells with the PBNZs adjuvant. This dual action induces a durable humoral immunity characterized by a high‐titer, antigen‐specific antibody response with a balanced Th1/Th2 immune profile. In the dextran sulfate sodium (DSS)‐induced acute colitis model, vaccination with the Ferritin‐PC@PBNZs vaccine markedly alleviated disease severity. This protective effect was attributed to the induction of high levels of specific antibody against inflammation‐associated PC antigen and the restoration of intestinal barrier integrity. Overall, this vaccine‐based immunotolerance therapy represents a promising long‐term therapeutic strategy for IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Sciences & Medical Engineering, Southeast University, Nanjing, China.
- Key Laboratory for Bio-Electromagnetic Environment and Advanced Medical Theragnostic, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, China.
- School of Chemistry and Chemical Engineering, Southeast University, Nanjing, Jiangsu, China.
- Engineering Medicine Research Group, and Nanjing Research Center for Biomedical Electron Microscopy (NRC-BEM), Medical School, Nanjing University, Nanjing, China.
ORCID-Profile: Ning Gu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Sheng, J., Huang, Y., Li, X., Liu, Y., Wu, Y., Zhang, Y., & Gu, N. (2026). A Prussian Blue Nanozyme‐Adjuvanted Vaccine Presenting Phosphocholine Antigens for Induction of Immunotolerance in Inflammatory Bowel Disease. Advanced Science. https://doi.org/10.1002/advs.202522027
Vancouver
Sheng J, Huang Y, Li X, Liu Y, Wu Y, Zhang Y, et al. A Prussian Blue Nanozyme‐Adjuvanted Vaccine Presenting Phosphocholine Antigens for Induction of Immunotolerance in Inflammatory Bowel Disease. Advanced Science. 2026. doi:10.1002/advs.202522027
BibTeX
@article{Sheng2026,
author = {Sheng, Jingyi and Huang, Yubo and Li, Xinyue and Liu, Yin and Wu, Yuehuang and Zhang, Yuxin and Gu, Ning},
title = {A Prussian Blue Nanozyme‐Adjuvanted Vaccine Presenting Phosphocholine Antigens for Induction of Immunotolerance in Inflammatory Bowel Disease},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.202522027}
}
EUVIMED